Immune checkpoint inhibitors are rapidly transforming the care of patients with esophagogastric cancer. Particularly, anti-PD-1 therapy has demonstrated promising efficacy in metastatic and resectable disease. In this review, the authors discuss landmark clinical trials, highlight challenges and opportunities in this field, and propose potential directions for future work.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hoc.2024.02.002 | DOI Listing |
Publication Analysis
Top Keywords
esophagogastric cancer
8
advances immunotherapy
4
immunotherapy esophagogastric
4
cancer immune
4
immune checkpoint
4
checkpoint inhibitors
4
inhibitors rapidly
4
rapidly transforming
4
transforming care
4
care patients
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!